Hanno Svoboda

Hanno Svoboda is the Lifecycle Leader for Trontinemab and Alzheimer’s at F. Hoffmann-La Roche AG in Switzerland. He previously held a leadership role in Neuroscience and Rare Diseases in Early Research and Development, where he also led asset teams in neurodegenerative diseases, including prasinezumab in Parkinson’s. Before joining Roche, he worked at Boston Consulting Group from 2007 to 2011, focusing on the healthcare industry's value chain from discovery to market access. Hanno is a neuroscientist by training and holds a PhD from the University of Cambridge.